Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia . DUBLIN, IRELAND, Apr 10, 2015 (Marketwired via COMTEX)
The Company submitted the Investigational New Drug (IND) application for ACTIMMUNE in the treatment of FA in February 2015 and announced plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance (FARA) and a sub-set of FARA's Collaborative Clinical Research Network (CCRN) study centers in FA.
Subscribe to:
Posts (Atom)
